DOCSLIB.ORG

Rosuvastatin 5Mg, 10Mg, 20Mg and 40Mg Film-Coated Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rosuvastatin 5Mg, 10Mg, 20Mg and 40Mg Film-Coated Tablets T00115-01 Malta Zejtun 190x500 PIL Package leaflet: Information for the user Rosuvastatin 5mg, 10mg, 20mg and 40mg Film-coated Tablets Read all of this leaflet carefully before you start Warnings and precautions taking this medicine because it contains important Talk to your doctor or pharmacist before taking information for you. Rosuvastatin Tablets: • Keep this leaflet. You may need to read it again. • If you have problems with your kidneys. • If you have any further questions, ask your doctor or • If you have problems with your liver. pharmacist. • If you have had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, • This medicine has been prescribed for you only. Do or a previous history of muscle problems when taking not pass it on to others. It may harm them, even if other cholesterol-lowering medicines. Tell your doctor their signs of illness are the same as yours. immediately if you have unexplained muscle aches or • If you get any side effects, talk to your doctor or pains especially if you feel unwell or have a fever. Also tell pharmacist. This includes any possible side effects your doctor or pharmacist if you have a muscle weakness not listed in this leaflet. See section 4. that is constant. • The full name of this medicine is Rosuvastatin 5mg, • If you are taking or have taken in the last 7 days a 10mg, 20mg and 40mg Film-coated Tablets but medicine called fusidic acid, (a medicine for bacterial within the leaflet it will be referred to as Rosuvastatin infection) orally or by injection. The combination of fusidic Tablets. acid and Rosuvastatin Tablets can lead to serious muscle problems (rhabdomyolysis). • If you regularly drink large amounts of alcohol. What is in this leaflet: • If your thyroid gland is not working properly. • If you take other medicines called fibrates to lower your 1 What Rosuvastatin Tablets are and what they cholesterol. Please read this leaflet carefully, even if you are used for have taken other medicines for high cholesterol before. 2 What you need to know before you take • If you take medicines used to fight the HIV infection e.g. Rosuvastatin Tablets ritonavir with lopinavir and/or atazanavir, please see “Other medicines and Rosuvastatin Tablets”. 3 How to take Rosuvastatin Tablets 4 Possible side effects Children and adolescents 5 • If the patient is under 6 years old: Rosuvastatin Tablets How to store Rosuvastatin Tablets should not be given to children younger than 6 years. 6 Contents of the pack and other information • If the patient is below 18 years of age: The Rosuvastatin 40mg Tablet is not suitable for use in children and 1 What Rosuvastatin Tablets are and what they adolescents below 18 years of age. are used for • If you are over 70 (as your doctor needs to choose the Rosuvastatin Tablets belong to a group of medicines called right start dose of Rosuvastatin Tablets to suit you). statins. • If you have severe respiratory failure. • If you are of Asian origin – that is Japanese, Chinese, You have been prescribed Rosuvastatin Tablets Filipino, Vietnamese, Korean and Indian. Your doctor needs because: to choose the right start dose of Rosuvastatin Tablets to - You have a high cholesterol level. This means you are at suit you. risk from a heart attack or stroke. Rosuvastatin Tablets are used in adults, adolescents and children 6 years or older If any of the above applies to you (or if you are not sure): to treat high cholesterol. • Do not take Rosuvastatin 40mg Tablets (the highest dose) and check with your doctor or pharmacist before you You have been advised to take a statin, because changing actually start taking any dose of Rosuvastatin Tablets. your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with In a small number of people, statins can affect the liver. This your cholesterol-lowering diet and exercise while you are is identified by a simple test which looks for increased levels taking Rosuvastatin Tablets of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) Or before and during treatment with Rosuvastatin Tablets. - You have other factors that increase your risk of having a heart attack, stroke or related health problems. Heart While you are on this medicine your doctor will monitor attack, stroke and other problems can be caused by a you closely if you have diabetes or are at risk of developing disease called Atherosclerosis. Atherosclerosis is due to a diabetes. You are likely to be at risk of developing diabetes build up of fatty deposits in your arteries. if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Why it is important to keep taking Rosuvastatin Tablets Other medicines and Rosuvastatin Tablets Rosuvastatin Tablets are used to correct the levels of fatty Tell your doctor or pharmacist if you are taking, have substances in the blood called lipids, the most common of recently taken or might take any other medicines. which is cholesterol. Tell your doctor if you are taking any of the following: There are different types of cholesterol found in the blood – ciclosporin (used for example, after organ transplants), “bad” cholesterol (LDL-C) and “good” cholesterol (HDL-C). warfarin or clopidogrel (or any other drug used for thinning - Rosuvastatin Tablets can reduce the “bad” cholesterol and the blood), fibrates (such as gemfibrozil, fenofibrate) or increase the “good” cholesterol. any other medicine used to lower cholesterol (such as - It works by helping to block your body’s production of ezetimibe), indigestion remedies (used to neutralise acid “bad” cholesterol. It also improves your body’s ability to in your stomach), erythromycin (an antibiotic), an oral remove it from your blood. contraceptive (the pill), hormone replacement therapy For most people, high cholesterol does not affect the way or anti-viral medications such as ritonavir with lopinavir they feel because it does not produce any symptoms. and/or atazanavir or simeprevir (used to treat infections, However, if it is left untreated, fatty deposits can build up in including HIV or hepatitis C infection – please see “Warnings the walls of your blood vessels causing them to narrow. and precautions”), dronedarone (an antiarrhythmic) and Sometimes, these narrowed blood vessels can get blocked itraconazole (an antifungal drug). If you need to take oral which can cut off the blood supply to the heart or brain fusidic acid to treat a bacterial infection you will need to leading to a heart attack or a stroke. If you correct your temporarily stop using this medicine. Your doctor will tell cholesterol levels, you can reduce your risk of having a you when it is safe to restart Rosuvastatin Tablets. Taking heart attack or stroke. Rosuvastatin Tablets with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See You need to keep taking Rosuvastatin Tablets, even if it has more information regarding rhabdomyolysis in section 4. got your cholesterol to the right level, because it prevents your cholesterol levels from creeping up again and causing The effects of these medicines could be changed by build up of fatty deposits. However, you should stop if your Rosuvastatin Tablets or they could change the effect of doctor tells you to do so, or if you have become pregnant. Rosuvastatin Tablets. Rosuvastatin Tablets with food and drink 2 What you need to know before you take You can take Rosuvastatin Tablets with or without food. Rosuvastatin Tablets Pregnancy and breast-feeding Do not take Rosuvastatin Tablets: Do not take Rosuvastatin Tablets if you are pregnant or • If you are allergic to rosuvastatin or any of the other breast-feeding. If you become pregnant while taking ingredients of this medicine (listed in section 6). Rosuvastatin Tablets stop taking them immediately and • If you are pregnant or breast-feeding. If you become tell your doctor. Women should avoid becoming pregnant pregnant while taking Rosuvastatin Tablets stop taking while taking Rosuvastatin Tablets by using suitable them immediately and tell your doctor. Women should contraception. avoid becoming pregnant while taking Rosuvastatin Tablets by using suitable contraception. Ask your doctor or pharmacist for advice before taking any • If you have liver disease. medicine. • If you have severe kidney problems. Driving and using machines • If you have repeated or unexplained muscle aches or Most people can drive a car and operate machinery while pains. using Rosuvastatin Tablets – it will not affect their ability. • If you take a drug called ciclosporin (used for example, However, some people feel dizzy during treatment with after organ transplants). Rosuvastatin Tablets. If you feel dizzy, consult your doctor If any of the above applies to you (or you are in doubt), before attempting to drive or use machines. please go back and see your doctor. Rosuvastatin Tablets contain lactose In addition, do not take Rosuvastatin 40mg If you have been told by your doctor that you have an Tablets (the highest dose): intolerance to some sugars (lactose or milk sugar), contact • If you have moderate kidney problems (if in doubt, please your doctor before taking Rosuvastatin Tablets. ask your doctor). For a full list of ingredients please see “Contents of the pack • If your thyroid gland is not working properly. and other information” below. • If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, Rosuvastatin Tablets contain Allura red AC (E129) or a previous history of muscle problems when taking May cause allergic reactions. other cholesterol-lowering medicines. • If you regularly drink large amounts of alcohol.
Load more

Recommended publications
  • Roszet (Rosuvastatin/Ezetimibe) – New Drug Approval
    Roszet (rosuvastatin/ezetimibe) – New drug approval • On March 23, 2021, the FDA approved Althera Pharmaceuticals’ Roszet (rosuvastatin/ezetimibe), in adults: as an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low- density lipoprotein cholesterol (LDL-C) and alone or as an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. • Roszet is a combination tablet containing rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor. Both components are available generically. • The approval of Roszet was based on previous efficacy data with rosuvastatin and ezetimibe. • Roszet is contraindicated in patients with: — Acute liver failure or decompensated cirrhosis — Hypersensitivity to rosuvastatin, ezetimibe, or any excipients in Roszet. Hypersensitivity reactions including anaphylaxis, angioedema, and erythema multiforme have been reported. • Warnings and precautions for Roszet include myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria and hematuria, and HbA1c and glucose levels. • The most common adverse reactions (> 2% and greater than statin alone) with ezetimibe co- administered with a statin are nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue. • The recommended dosage range of Roszet is 5 mg/10 mg to 40 mg/10 mg once daily. — The recommended dose of Roszet depends on a patient’s indication for usage, LDL-C, and individual risk for cardiovascular events. — The starting dosage for patients switching to Roszet from co-administration of a statin and ezetimibe is based on an equivalent dose of rosuvastatin and 10 mg of ezetimibe.
    [Show full text]
  • Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk Of
    biomedicines Article Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study Wei-Ting Liu 1, Chin Lin 2,3,4, Min-Chien Tsai 5, Cheng-Chung Cheng 6, Sy-Jou Chen 7,8, Jun-Ting Liou 6 , Wei-Shiang Lin 6, Shu-Meng Cheng 6, Chin-Sheng Lin 6,* and Tien-Ping Tsao 6,9,* 1 Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 2 School of Public Health, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 3 School of Medicine, National Defense Medical Center, Taipei 11490, Taiwan 4 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan, 5 Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 6 Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] (C.-C.C.); [email protected] (J.-T.L.); [email protected] (W.-S.L.); [email protected] (S.-M.C.) 7 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 8 Graduate Institute of Injury Prevention and Control, College of Public Health and Nutrition, Taipei Medical University, Taipei 11031, Taiwan 9 Division of Cardiology, Cheng Hsin General Hospital, Taipei 11220, Taiwan * Correspondence: [email protected] (C.-S.L.); [email protected] (T.-P.T.); Tel.: +886-2-6601-2656 (C.-S.L.); +886-2-2826-4400 (T.-P.T.) Received: 25 October 2020; Accepted: 11 November 2020; Published: 13 November 2020 Abstract: Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM).
    [Show full text]
  • Nustendi, INN-Bempedoic Acid, Ezetimibe
    Summary of risk management plan for Nustendi (Bempedoic acid/Ezetimibe) This is a summary of the risk management plan (RMP) for Nustendi. The RMP details important risks of Nustendi, how these risks can be minimized, and how more information will be obtained about Nustendi's risks and uncertainties (missing information). Nustendi's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Nustendi should be used. This summary of the RMP for Nustendi should be read in the context of all this information, including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Nustendi's RMP. I. The Medicine and What It Is Used For Nustendi is authorized for treatment of primary hypercholesterolemia in adults, as an adjunct to diet (see SmPC for the full indication). It contains bempedoic acid as the active substance and it is given by mouth. Further information about the evaluation of Nustendi’s benefits can be found in Nustendi’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi II. Risks Associated With the Medicine and Activities to Minimize or Further Characterize the Risks Important risks of Nustendi, together with measures to minimize such risks and the proposed studies for learning
    [Show full text]
  • SUMMARY of the PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT <Invented Name> 10 Mg/10 Mg Film-Coated Tablets
    SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Invented name> 10 mg/10 mg film-coated tablets <Invented name> 20 mg/10 mg film-coated tablets <Invented name> 40 mg/10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <Invented name> 10 mg/10 mg: Each film-coated tablet contains 10 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 20 mg/10 mg: Each film-coated tablet contains 20 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 40 mg/10 mg: Each film-coated tablet contains 40 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. Excipient with known effect: <Invented name> 10 mg/10 mg: Each film-coated tablet contains 111.2 mg of lactose (as lactose monohydrate). <Invented name> 20 mg/10 mg: Each film-coated tablet contains 168.6 mg of lactose (as lactose monohydrate). <Invented name> 40 mg/10 mg: Each film-coated tablet contains 286.0 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) <Invented name> 10 mg/10 mg: white to off-white oblong film-coated tablets. <Invented name> 20 mg/10 mg: yellow to light yellow oblong film-coated tablets. <Invented name> 40 mg/10 mg: pink oblong film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH) <Invented name> is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
    [Show full text]
  • Product Monograph Crestor
    PRODUCT MONOGRAPH Pr CRESTOR® rosuvastatin calcium Tablets, 5, 10, 20 and 40 mg LIPID METABOLISM REGULATOR AstraZeneca Canada Inc. Date of Revision: May 14, 2020 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No: 235939 CRESTOR® is a registered trademark of the AstraZeneca group of companies. Licensed from Shionogi & Co. Ltd. Osaka, Japan. COPYRIGHT 2003 – 2020 ASTRAZENECA CANADA INC. Page 1 of 46 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................3 SUMMARY PRODUCT INFORMATION ..............................................................3 INDICATIONS AND CLINICAL USE....................................................................3 CONTRAINDICATIONS ........................................................................................4 WARNINGS AND PRECAUTIONS .......................................................................5 ADVERSE REACTIONS ...................................................................................... 10 DRUG INTERACTIONS....................................................................................... 16 DOSAGE AND ADMINISTRATION.................................................................... 22 OVERDOSAGE..................................................................................................... 25 ACTION AND CLINICAL PHARMACOLOGY................................................... 25 STORAGE AND STABILITY............................................................................... 27 DOSAGE
    [Show full text]
  • Bempedoic Acid) Tablets, for Oral Use Most Common (Incidence ≥ 2% and Greater Than Placebo) Adverse Reactions Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Tendon Rupture: Tendon rupture has occurred. Discontinue NEXLETOL These highlights do not include all the information needed to use at the first sign of tendon rupture. Avoid NEXLETOL in patients who NEXLETOL™ safely and effectively. See full prescribing information have a history of tendon disorders or tendon rupture. (5.2) for NEXLETOL. --------------------------------ADVERSE REACTIONS----------------------------­ NEXLETOL (bempedoic acid) tablets, for oral use Most common (incidence ≥ 2% and greater than placebo) adverse reactions Initial U.S. Approval: 2020 are upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, ----------------------------INDICATIONS AND USAGE--------------------------­ and elevated liver enzymes. (6.1) NEXLETOL is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and maximally tolerated statin therapy for the To report SUSPECTED ADVERSE REACTIONS, contact Esperion at treatment of adults with heterozygous familial hypercholesterolemia or 833-377-7633 (833 ESPRMED) or FDA at 1-800-FDA-1088 or established atherosclerotic cardiovascular disease who require additional www.fda.gov/medwatch. lowering of LDL-C. (1) --------------------------------DRUG INTERACTIONS----------------------------­ Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity • Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin and mortality has not been
    [Show full text]
  • Rosuvastatin (Crestor)
    What is most important to remember? If you have questions: Strong Internal Medicine • Use this medicine as directed by your doctor Ask your doctor, nurse or pharmacist for more information about rosuvastatin • It is important to continue taking (Crestor®) this medicine even if you feel normal. Most people with high cholesterol or triglycerides do not feel sick • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using Strong Internal Medicine rosuvastatin (Crestor®) 601 Elmwood Avenue th • Contact your prescriber right away Ambulatory Care Facility, 5 Floor Rochester, NY 14642 if you have severe muscle pain or Phone: (585) 275 -7424 weakness Rosuvastatin Visit our website at: (Crestor®): • Follow the diet and lifestyle www.urmc.rochester.edu/medicine/ - genera medicine/patientcare/ Important Patient Information changes that you talked about l- with your doctor in addition to taking your prescribed medicine to get the greatest health benefits What does rosuvastatin (Crestor®) do? Who should know I am taking rosuvastatin (Crestor®)? What are some things that I need to be aware of when • It is used to lower the level of bad cholesterol (LDL), • Keep a list of all your medicines (prescription, natural taking rosuvastatin (Crestor®)? raise the level of good cholesterol (HDL), and lower products, supplements, vitamins, over-the-counter) and • Tell your doctor or pharmacist if you have a “statin” triglycerides (TG) in the body give
    [Show full text]
  • Efficacy of Combination Therapy of Rosuvastatin and Ezetimibe Vs
    Original Article DOI: 10.7860/JCDR/2017/30458.11004 Efficacy of Combination Therapy Internal Medicine Section of Rosuvastatin and Ezetimibe vs Rosuvastatin Monotherapy on Lipid Profile of Patients with Coronary Artery Disease SANDEEP JOSHI1, RUBY SHARMA2, HARBIR KAUR RAO3, UDIT NARANG4, NITIN GUPTA5 ABSTRACT baseline investigations and lifestyle modifications, Group I Introduction: Dyslipidaemia is one of the most important was started on rosuvastatin 10 mg once daily, while Group modifiable risk factor for the development of Coronary II was started on rosuvastatin 10 mg+ezetimibe 10 mg daily. Artery Disease (CAD). Although, statins are established as The fasting serum lipid profile was repeated initially after first line lipid-lowering therapy, they may not be able to 12 weeks and then after 24 weeks. The two groups were achieve treatment goals in significant number of patients. observed for side effects which were noted. Combination therapy of statin with a non-statin drug like Results: The combination therapy of rosuvastatin and Ezetimibe is a therapeutic option. ezetimibe resulted in significantly higher change in all Aim: To compare the efficacy and safety of Rosuvastatin/ lipid parameters (LDL-C, TC, TG, HDL-C) as compared to Ezetimibe combination therapy vs Rosuvastatin alone on the treatment with rosuvastatin alone. There was no difference in lipid profile of patients with CAD in Northern India. the adverse effects seen after treatment in the two groups. Materials and Methods: This randomized prospective Conclusion: Our study showed that combination therapy study was conducted on 80 patients of CAD presenting of ezetimibe with rosuvastatin can be used as an effective to Department of Medicine, Government Medical College, and safe therapy in high risk patients of CAD, especially in Patiala, Punjab, India.
    [Show full text]
  • CP.PMN.237 Bempedoic Acid (Nexletol)
    Clinical Policy: Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) Reference Number: CP.PMN.237 Effective Date: 09.01.20 Last Review Date: 02.21 Revision Log Line of Business: Commercial, HIM, Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are adenosine triphosphate-citrate lyase (ACL) inhibitors requiring prior authorization: bempedoic acid (Nexletol™) and bempedoic acid/ezetimibe (Nexlizet™). Nexlizet contains ezetimibe, which is a cholesterol absorption inhibitor. FDA Approved Indication(s) Nexletol and Nexlizet are indicated for use as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Limitation(s) of use: The effect of Nexletol and Nexlizet on cardiovascular morbidity and mortality has not been determined. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Nexletol and Nexlizet are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Heterozygous Familial Hypercholesterolemia and Atherosclerotic Cardiovascular Disease (must meet all): 1. Diagnosis of one of the following (a or b): a. ASCVD as evidenced by a history of any one of the following conditions (i-vii): i. Acute coronary syndromes; ii. Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging); iii.
    [Show full text]
  • Rosuvastatin
    Rosuvastatin Rosuvastatin Systematic (IUPAC) name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan- 2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Clinical data Trade names Crestor AHFS/Drugs.com monograph MedlinePlus a603033 Pregnancy AU: D category US: X (Contraindicated) Legal status AU: Prescription Only (S4) UK: Prescription-only (POM) US: ℞-only Routes of oral administration Pharmacokinetic data Bioavailability 20%[1] Protein binding 88%[1] Metabolism Liver (CYP2C9(major) andCYP2C19-mediated; only minimally (~10%) metabolised)[1] Biological half-life 19 hours[1] Excretion Faeces (90%)[1] Identifiers CAS Registry 287714-41-4 Number ATC code C10AA07 PubChem CID: 446157 IUPHAR/BPS 2954 DrugBank DB01098 UNII 413KH5ZJ73 KEGG D01915 ChEBI CHEBI:38545 ChEMBL CHEMBL1496 PDB ligand ID FBI (PDBe, RCSB PDB) Chemical data Formula C22H28FN3O6S Molecular mass 481.539 SMILES[show] InChI[show] (what is this?) (verify) Rosuvastatin (marketed by AstraZenecaas Crestor) 10 mg tablets Rosuvastatin, marketed as Crestor, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fourth- highest selling drug in the United States, accounting for approx. $5.2 billion in sales in 2013.[2] Contents [hide] 1Medical uses 2Side effects and contraindications 3Drug interactions 4Structure 5Mechanism of action 6Pharmacokinetics 7Indications and regulation
    [Show full text]
  • Bempedoic Acid
    Drug and Biologic Coverage Policy Effective Date ............................................. 7/15/2020 Next Review Date ......................................... 7/1/2021 Coverage Policy Number .................................. 2015 Bempedoic acid Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Genetic Testing of Heritable Disorders FDA Approved Indications ................................... 4 Recommended Dosing ........................................ 4 General Background ............................................ 4 Coding/Billing Information .................................... 7 References .......................................................... 7 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit
    [Show full text]
  • Rosuvastatin (Crestor®) VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
    National PBM-MAP Drug Monograph Rosuvastatin (Crestor®) VHA Pharmacy Benefits Management Strategic Healthcare Group and The Medical Advisory Panel Executive Summary Efficacy In 6 randomized, head-to-head statin comparative clinical trials, 10 mg of rosuvastatin resulted in a reduction in LDL-C of between 43-49%. The approximate equivalent daily dose of simvastatin and atorvastatin to rosuvastatin 10 mg are 80 mg and 40 mg, respectively. With regard to HDL-C elevation and triglyceride lowering, rosuvastatin produced changes similar to that seen with the other statins, with few exceptions. There are currently no published clinical trials demonstrating a reduction in health outcomes with rosuvastatin. Safety In pre-marketing controlled clinical trials, over 10,000 patients have been exposed to rosuvastatin. The most common adverse events included myalgia, constipation, asthenia, abdominal pain and nausea and were similar to those seen with other statins. Clinically significant elevation in liver function tests (LFTs, >3X upper limit of normal) was reported in 0-0.4% of patients receiving doses up to 40 mg daily. Clinically significant elevation in creatine kinase (CK, >10X upper limit of normal) was reported in 0.2-0.4% of patients taking up to 40 mg daily. Symptomatic myopathy, with significant elevation in CK, was reported in 0.1% of patients taking up to 40 mg of rosuvastatin daily. In the rosuvastatin clinical trials program, one case of rhabdomyolysis was reported with the 10 mg dose and 7 cases with the 80 mg dose. Rhabdomyolysis was not observed in pre-marketing clinical trials of other available statins. In the Stellar trial, 2 patients on rosuvastatin 80 mg per day developed renal failure of unknown etiology with one requiring short-term hemodialysis.
    [Show full text]